Estrella Immunopharma nears completion of SPAC listing
The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…
Recent Articles
RELATED ARTICLES
-
Seyond may get stuck in slow-moving SPAC lane to Hong Kong listing
7855.HK -
ZG Group set to forge Hong Kong’s second De-SPAC listing
2572.HK
- Youlife chases SPAC listing after death of Hong Kong IPO
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- China’s hydrogen drive powers up SPAC listing by Scage
